Karin Ludwig
Nessuna posizione attualmente
Profilo
Dr. Karin Ludwig, MD, is Vice President-Clinical Development at Acucela, Inc.
Dr. Ludwig was previously employed as Chief Medical Officer by Alacrity Biosciences, Inc., Senior Director by Pfizer Inc., and Senior Vice President-Clinical Research by Amicus Therapeutics, Inc.
She received her doctorate degree from the University of Freiburg.
Precedenti posizioni note di Karin Ludwig
| Società | Posizione | Fine |
|---|---|---|
| ACUCELA INC | Corporate Officer/Principal | - |
| AMICUS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Alacrity Biosciences, Inc.
 Alacrity Biosciences, Inc. Medical DistributorsDistribution Services Alacrity Biosciences, Inc. develops and markets pharmaceutical products, which are used in ophthalmology. The company was founded on November 9, 2006 and is headquartered in New York, NY. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Karin Ludwig
| University of Freiburg | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Alacrity Biosciences, Inc.
Alacrity Biosciences, Inc. Medical DistributorsDistribution Services Alacrity Biosciences, Inc. develops and markets pharmaceutical products, which are used in ophthalmology. The company was founded on November 9, 2006 and is headquartered in New York, NY. | Distribution Services |
Acucela, Inc.
 Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Karin Ludwig
